Literature DB >> 19244203

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.

Magali Meyer1, François Huaux, Ximena Gavilanes, Sybille van den Brûle, Patrick Lebecque, Sandra Lo Re, Dominique Lison, Bob Scholte, Pierre Wallemacq, Teresinha Leal.   

Abstract

Macrophages phagocyte pathogenic microorganisms and orchestrate immune responses by producing a variety of inflammatory mediators. The cystic fibrosis (CF) transmembrane conductance regulator chloride channel has been reported to be of pivotal importance for macrophage functions. The exact phenotype and role of macrophages in CF is still unknown. Alveolar and peritoneal macrophages were monitored in CF mice homozygous for the F508 del mutation and in wild-type control animals. Classical (M1) and alternative (M2) macrophage polarization and responses to LPS from Pseudomonas aeruginosa were investigated, and the effect of azithromycin was examined in both cell populations. We show that alveolar macrophage counts were 1.7-fold higher in CF as compared with wild-type mice. The macrophage-related chemokine, chemokine C-C motif ligand (CCL)-2, was found to be at least 10-fold more abundant in the alveolar space of mutant mice. Cell count and CCL-2 protein levels were also increased in the peritoneal cavity of CF mice. Both M1 and M2 macrophage polarization were significantly enhanced in alveolar and peritoneal cells from F508del-CF mice as compared with control animals. LPS-stimulated expression of proinflammatory mediators, such as nitric oxide synthase-2, IL-1beta, and CCL-2, was increased, whereas anti-inflammatory IL-10 expression was decreased in CF macrophages. Azithromycin, added to cell cultures at 1 mg/liter, significantly reduced proinflammatory cytokine expression (IL-1beta, CCL-2, TNF-alpha) in M1-induced CF and wild-type alveolar macrophages. Our findings indicate that CF macrophages are ubiquitously accumulated, and that these cells are polarized toward classical and alternative activation status. Azithromycin down-regulates inflammatory cytokine production by M1-polarized CF alveolar macrophages.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244203     DOI: 10.1165/rcmb.2008-0155OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  42 in total

1.  The anti-inflammatory mechanism of heme oxygenase-1 induced by hemin in primary rat alveolar macrophages.

Authors:  Chen Hualin; Xu Wenli; Liu Dapeng; Li Xijing; Pan Xiuhua; Pang Qingfeng
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Authors:  Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 3.  Macrophages: plastic solutions to environmental heterogeneity.

Authors:  Selma Giorgio
Journal:  Inflamm Res       Date:  2013-07-20       Impact factor: 4.575

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

5.  A Flow Cytometric Method for Isolating Cystic Fibrosis Airway Macrophages from Expectorated Sputum.

Authors:  Katherine B Hisert; W Conrad Liles; Anne M Manicone
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

Review 6.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

7.  Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Don Hayes; Michael I Anstead; Jamshed F Kanga; Robert J Kuhn; Heather M Bush; David J Feola
Journal:  J Cyst Fibros       Date:  2013-09-07       Impact factor: 5.482

8.  Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.

Authors:  V Balloy; A Deveaux; D Lebeaux; O Tabary; P le Rouzic; J M Ghigo; P F Busson; P Y Boëlle; J Guez Guez; U Hahn; A Clement; M Chignard; H Corvol; M Burnet; L Guillot
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Cynthia Mattingly; Jessica M Breslow-Deckman; David J Feola
Journal:  J Antimicrob Chemother       Date:  2012-12-17       Impact factor: 5.790

10.  Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages.

Authors:  Keiko Yamauchi; Yoko Shibata; Tomomi Kimura; Shuichi Abe; Sumito Inoue; Daisuke Osaka; Michiko Sato; Akira Igarashi; Isao Kubota
Journal:  Int J Biol Sci       Date:  2009-10-23       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.